DCISionRT(R) by PreludeDx(TM) Receives Advanced Diagnostic Laboratory Test (ADLT) Status Approval from the Centers for Medicare and Medicaid Services

LAGUNA HILLS, Calif., March 28, 2023 -- (Healthcare Sales & Marketing Network) -- Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that the Centers for Medicare & Med... Diagnostics, Oncology PreludeDx, DCISionRT test, ductal carcinoma in situ

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2047938

Source: HSMN NewsFeed - March 28, 2023 Category: Pharmaceuticals Source Type: news